GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Novo Nordisk A/S NVO · USD

Health Care · US listing · 🇺🇸 United States

Compare

41.38

+2.65%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$47.79bn

FY2016FY2025

Net income

$15.84bn

FY2016FY2025

Free cash flow

$4.48bn

FY2016FY2025

Shareholders' equity

$30.00bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$47.79bn$44.90bn$35.91bn$27.36bn$21.77bn$19.63bn$18.87bn$17.29bn$17.27bn$17.28bn
Gross profit$38.70bn$38.02bn$30.38bn$22.96bn$18.11bn$16.39bn$15.76bn$14.57bn$14.54bn$14.63bn
Research and development$8.05bn$7.43bn$5.02bn$3.72bn$2.75bn$2.39bn$2.20bn$2.29bn$2.17bn$2.25bn
Operating income$20.23bn$19.84bn$15.86bn$11.57bn$9.10bn$8.37bn$8.12bn$7.32bn$7.57bn$7.49bn
Net income$15.84bn$15.62bn$12.94bn$8.59bn$7.38bn$6.52bn$6.02bn$5.97bn$5.90bn$5.86bn
Diluted earnings per share3.563.502.891.901.611.401.271.231.191.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$83.95bn$72.02bn$48.63bn$37.30bn$30.08bn$3.68bn$2.92bn$17.13bn$15.83bn$15.08bn
Cash and short-term investments$4.17bn$4.07bn$4.67bn$3.65bn$2.70bn$324.2m$359.4m$2.42bn$2.92bn$3.20bn
Total liabilities$53.94bn$49.84bn$32.15bn$24.40bn$19.14bn$2.07bn$1.58bn$9.11bn$8.12bn$8.08bn
Debt$20.25bn$15.89bn$4.18bn$3.99bn$4.12bn$637.5m$499.5m$79.6m$261.9m$35.4m
Shareholders' equity$30.00bn$22.19bn$16.48bn$12.91bn$10.94bn$1.61bn$1.34bn$8.02bn$7.70bn$7.00bn
Shares outstanding4,448m4,461m4,477m4,523m4,586m4,656m4,733m4,844m4,947m5,034m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$18.42bn$18.70bn$16.84bn$12.20bn$8.50bn$8.03bn$7.23bn$6.90bn$6.37bn$7.47bn
Capital spending−$13.93bn−$7.93bn−$6.01bn−$2.28bn−$1.14bn−$3.41bn−$1.74bn−$1.92bn−$1.34bn−$1.28bn
Free cash flow$4.48bn$10.77bn$10.83bn$9.92bn$7.36bn$4.62bn$5.50bn$4.98bn$5.03bn$6.19bn
Dividends paid−$8.00bn−$6.83bn−$4.91bn−$3.91bn−$3.33bn−$3.11bn−$3.00bn−$2.95bn−$2.91bn−$3.68bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$12.14bn$14.97bn$12.24bn$11.59bn$11.88bn$12.07bn$13.25bn$11.03bn
Gross profit$9.49bn$12.87bn$9.90bn$8.82bn$9.90bn$10.08bn$11.23bn$9.28bn
Operating income$4.18bn$9.22bn$5.29bn$3.66bn$5.17bn$6.00bn$5.68bn$5.23bn
Net income$3.25bn$7.51bn$4.16bn$3.09bn$4.10bn$4.49bn$4.37bn$4.22bn
Diluted earnings per share0.731.690.930.700.921.010.980.95
Cash from operations$8.54bn$3.72bn$1.18bn$7.13bn$6.31bn$3.80bn$1.90bn$6.78bn
Capital spending−$1.98bn−$1.86bn−$6.78bn−$2.38bn−$2.52bn−$2.25bn−$2.56bn−$1.93bn
Free cash flow$6.56bn$1.86bn−$5.60bn$4.75bn$3.79bn$1.55bn−$658.0m$4.85bn
Total assets$91.99bn$86.47bn$83.95bn$79.21bn$74.55bn$75.64bn$72.02bn$61.45bn
Cash and short-term investments$6.96bn$3.34bn$4.17bn$5.04bn$2.93bn$6.42bn$4.07bn$11.58bn
Debt$21.67bn$22.63bn$20.25bn$15.65bn$15.35bn$18.36bn$15.89bn$8.81bn
Shareholders' equity$34.22bn$31.40bn$30.00bn$26.27bn$25.99bn$21.42bn$22.19bn$18.64bn

Financial ratios

Data as of 5 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin81.0%84.7%84.6%83.9%83.2%83.5%
Operating margin42.3%44.2%44.2%42.3%41.8%42.6%
Net margin33.1%34.8%36.0%31.4%33.9%33.2%
Return on equity52.8%70.4%78.5%66.5%67.5%404.8%
Return on assets18.9%21.7%26.6%23.0%24.6%176.9%
Free cash flow yield100.9%82.9%70.8%44.4%29.2%34.1%
Revenue growth6.4%25.0%31.3%25.7%10.9%4.0%
Earnings growth1.4%20.7%50.7%16.3%13.3%8.2%
Current ratio0.80x0.74x0.82x0.89x0.86x0.94x
Debt to equity0.67x0.68x0.21x0.27x0.33x0.12x
Equity ratio35.7%30.8%33.9%34.6%36.4%43.7%
Interest coverage31.10x78.26x189.25x197.91x203.54x138.78x
R&D as a share of sales16.8%16.6%14.0%13.6%12.6%12.2%
Buybacks as a share of market value0.3%0.4%1.0%1.4%1.5%1.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue20.4%19.5%11.1%
Operating income20.5%19.3%10.2%
Net income22.6%19.4%11.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin82.8%83.4%83.4%83.7%
Operating margin43.2%43.3%43.1%43.2%
Net margin33.9%34.0%33.9%33.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings14.324.635.835.634.824.922.718.722.515.4
Price to sales4.78.512.911.211.88.37.36.57.75.2

Market value over time

31 Oct 2016 to 4 Sept 2026, in USD

$44.97bn$206.71bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-55%6%53%26%44%24%28%-14%48%-38%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 20 Sept 2023
  • 5-for-1 split · 9 Jan 2014
  • 2-for-1 split · 17 Dec 2007
  • 5-for-2 split · 11 Apr 2001
  • 4-for-1 split · 18 Apr 1994

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.